Clarification: Drug Risk in Patients with Glaucoma

The Medical Letter on Drugs and Therapeutics

FROM
ISSUE

1106

June 11, 2001

View Complete Issue Table of Contents 2019

Clarification: Drug Risk in Patients with Glaucoma

Show Related
Terms Hide Related
Terms

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2001 Jun 11;43(1106):52

Disclosures

Objective(s)

Select a term to see related articles Detrol LA Ditropan XL glaucoma overactive bladder oxybutynin tolterodine

SUMMARY: The Medical Letter article on Detrol LA and Ditropan XL (vol.43, page 28, April 2, 2001) stated that these drugs should not be used in patients with glaucoma. That statement is misleading because anticholinergic or antimuscarinic drugs present a risk only to patients with untreated angle-closure (also called narrow-angle) glaucoma, which accounts for 10% of glaucomas in the USA. These drugs have no effect on the more common open-angle glaucoma, or on angle-closure glaucoma that has been treated by laser iridectomy.

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.